CEL-SCI (CVM) Competitors $2.49 -0.03 (-1.19%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$2.48 -0.01 (-0.24%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. GRCE, MRNS, MAAQ, ALLK, SXTC, INKT, RANI, SCYX, DYAI, and FBLGShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Grace Therapeutics (GRCE), Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Allakos (ALLK), China SXT Pharmaceuticals (SXTC), MiNK Therapeutics (INKT), Rani Therapeutics (RANI), SCYNEXIS (SCYX), Dyadic International (DYAI), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors Grace Therapeutics Marinus Pharmaceuticals Mana Capital Acquisition Allakos China SXT Pharmaceuticals MiNK Therapeutics Rani Therapeutics SCYNEXIS Dyadic International FibroBiologics Grace Therapeutics (NASDAQ:GRCE) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Do institutionals & insiders hold more shares of GRCE or CVM? 6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 13.5% of Grace Therapeutics shares are held by insiders. Comparatively, 9.9% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend GRCE or CVM? Grace Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 283.39%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Grace Therapeutics is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GRCE or CVM more profitable? Grace Therapeutics' return on equity of -19.45% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -19.45% -16.99% CEL-SCI N/A -238.05%-104.65% Does the media prefer GRCE or CVM? In the previous week, Grace Therapeutics' average media sentiment score of 0.00 equaled CEL-SCI'saverage media sentiment score. Company Overall Sentiment Grace Therapeutics Neutral CEL-SCI Neutral Which has higher earnings and valuation, GRCE or CVM? Grace Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$9.57M-$0.89-3.52CEL-SCIN/AN/A-$26.92M-$12.61-0.20 Which has more volatility & risk, GRCE or CVM? Grace Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. SummaryGrace Therapeutics beats CEL-SCI on 9 of the 10 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$7.55M$205.22M$5.56B$20.73BDividend YieldN/AN/A5.24%3.72%P/E Ratio-5.19N/A19.9626.30Price / SalesN/A223.65419.5638.45Price / CashN/A22.4426.2118.22Price / Book16.605.618.034.61Net Income-$26.92M-$96.61M$3.18B$983.39M7 Day Performance3.75%-0.57%2.93%2.79%1 Month Performance4.62%-3.74%1.72%4.37%1 Year Performance-93.14%10.50%34.39%15.08% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI0.0731 of 5 stars$2.49-1.2%N/A-93.1%$7.55MN/A-5.1943High Trading VolumeGRCEGrace Therapeutics1.764 of 5 stars$2.93-2.3%$12.00+309.6%N/A$30.42MN/A-2.53N/AHigh Trading VolumeMRNSMarinus Pharmaceuticals2.3299 of 5 stars$0.55-0.2%$3.92+613.3%-54.2%$30.32M$30.99M-0.22110News CoverageMAAQMana Capital AcquisitionN/A$3.71-4.6%N/A+603.6%$30.14MN/A0.001ALLKAllakos2.8718 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190SXTCChina SXT Pharmaceuticals0.1391 of 5 stars$1.84flatN/A-78.1%$29.12M$1.93M0.0090News CoverageINKTMiNK Therapeutics3.2705 of 5 stars$7.48+3.0%$37.50+401.3%-25.3%$28.94MN/A-2.9730RANIRani Therapeutics1.5126 of 5 stars$0.49-2.1%$7.33+1,396.6%-85.6%$28.77M$1.03M-0.49110SCYXSCYNEXIS0.2585 of 5 stars$0.73-0.6%N/A-60.9%$28.65M$3.75M-1.3060DYAIDyadic International1.9943 of 5 stars$0.94+2.9%$6.00+539.7%-35.3%$27.44M$3.49M-4.697News CoverageGap UpFBLGFibroBiologics2.2861 of 5 stars$0.72+3.6%$13.00+1,703.3%-87.0%$26.61MN/A-3.4310Gap Up Related Companies and Tools Related Companies Grace Therapeutics Competitors Marinus Pharmaceuticals Competitors Mana Capital Acquisition Competitors Allakos Competitors China SXT Pharmaceuticals Competitors MiNK Therapeutics Competitors Rani Therapeutics Competitors SCYNEXIS Competitors Dyadic International Competitors FibroBiologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVM Stock Alerts